Miglitol
| | |
| Miglitol
| |
| Systematic (IUPAC) name | |
| (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl) piperidine-3,4,5-triol | |
| Identifiers | |
| CAS number | |
| ATC code | A10 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C8H17NO5 |
| Mol. mass | 207.224 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Dose-dependent |
| Protein binding | Negligible (<4.0%) |
| Metabolism | Nil |
| Half life | 2 hours |
| Excretion | Renal (95%) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Miglitol | |
|
Articles | |
|---|---|
|
Most recent articles on Miglitol | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Miglitol at Clinical Trials.gov Clinical Trials on Miglitol at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Miglitol
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Directions to Hospitals Treating Miglitol Risk calculators and risk factors for Miglitol
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Miglitol | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
For patient information, click here
Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.
Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.
In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.
See also
Oral antidiabetic drugs and Insulin analogs (A10) | |
|---|---|
| Biguanides | Metformin |
| Sulfonylureas | Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide |
| Alpha-glucosidase inhibitors | Acarbose, Miglitol, Voglibose |
| Thiazolidinediones (TZD) | Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡ |
| Meglitinides | Nateglinide, Repaglinide, Mitiglinide |
| Dipeptidyl peptidase-4 (DPP-4) inhibitors | Alogliptin†, Saxagliptin†, Sitagliptin, Vildagliptin, Linagliptin† |
| Glucagon-like peptide-1 analog | Exenatide, Liraglutide†, Albiglutide† |
| Amylin analog | Pramlintide |
| Insulin analogs | fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir) |
| Dual PPAR agonists | Aleglitazar†, Muraglitazar§, Tesaglitazar§ |
| SGLT2 inhibitor | Dapagliflozin†, Remogliflozin† |
| †Undergoing clinical trials. ‡ Withdrawn from market. §Development halted. | |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies